Risk of Late Relapse or Reinfection with Hepatitis C Virus after Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis

Clinical Infectious Diseases

Volumn 62, Issue 6, 2015, Pages 683-694

  Simmons, Bryony ^a   Saleem, Jawaad ^a   Hill, Andrew ^b   Riley, Richard D ^c   Cooke, Graham S ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c KEELE UNIVERSITY   (United Kingdom)

Author keywords

Hepatitis C; Recurrence; Reinfection; Relapse; Sustained virologic response

Indexed keywords

VIRUS RNA; ANTIVIRUS AGENT; RIBAVIRIN;

ARTICLE; COHORT ANALYSIS; CONFIDENCE INTERVAL; DRUG USE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOW RISK PATIENT; META ANALYSIS; MIXED INFECTION; PRIORITY JOURNAL; PRISONER; RECURRENCE RISK; RECURRENT DISEASE; REINFECTION; RELAPSE; SUSTAINED VIROLOGICAL RESPONSE; SYSTEMATIC REVIEW; TREATMENT RESPONSE; ADOLESCENT; ADULT; CHRONIC HEPATITIS C; FEMALE; GENETICS; HEPACIVIRUS; ISOLATION AND PURIFICATION; MALE; RISK FACTOR; SUSTAINED VIROLOGIC RESPONSE; VIROLOGY; VIRUS LOAD; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIVIRAL AGENTS; COINFECTION; DRUG USERS; FEMALE; FOLLOW-UP STUDIES; HEPACIVIRUS; HEPATITIS C; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; MALE; RECURRENCE; RIBAVIRIN; RISK FACTORS; RNA, VIRAL; SUSTAINED VIROLOGIC RESPONSE; VIRAL LOAD; YOUNG ADULT;

EID: 84960075820     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ948     Document Type: Article

References (60)

1. Gerlach J, Diepolder H, Zachoval R, et al. Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003; 125:80-8.
2. Thein H, Yi Q, Dore G, Krahn M. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48:418-31.
3. Naghavi M, Wang H, Lozano R, et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385:117-71.
4. Mohd Hanafiah K, Groeger J, Flaxman A, Wiersma S. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57:1333-42.
5. Pearlman B, Traub N. Sustained virologic response to antiviral therapy for chronic hepatitis C virus infection: a cure and so much more. Clin Infect Dis 2011; 52:889-900.
6. Simmons B, Saleem J, Heath K, Cooke GS, Hill A. Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis 2015; 61:730-40.
7. Bruggmann P, Berg T, Ovrehus A, et al. Historical epidemiology of hepatitis C virus (HCV) in selected countries. J Viral Hepat 2014; 21(suppl 1):5-33.
8. Webster D, Klenerman P, Dusheiko G. Hepatitis C. Lancet 2015; 385:1124-35.
9. Boseley S. Hepatitis C drug delayed by NHS due to high cost. [Online]. 2015. Available from: http://www.theguardian.com/society/2015/jan/16/sofosbuvirhepatitis-c-drug-nhs. Accessed 24 March 2015.
10. Lemoine M, Nayagam S, Thursz M. Viral hepatitis in resource-limited countries and access to antiviral therapies: current and future challenges. Future Virol 2013; 8:371-80.
11. Nelson P,Mathers B, Cowie B, et al. The epidemiology of viral hepatitis among people who inject drugs: results of global systematic reviews. Lancet 2011; 378:571-83.
12. Shepard C, Finelli L, Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-67.
13. Medrano J, Barreiro P, Resino S, et al. Rate and timing of hepatitis C virus relapse after a successful course of pegylated interferon plus ribavirin in HIV-infected and HIV-uninfected patients. Clin Infect Dis 2009; 49:1397-401.
14. Formann E, Steindl-Munda P, Hofer H, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to various forms of interferonbased anti-viral therapy. Aliment Pharmacol Ther 2006; 23:507-11.
15. Torriani F, Rodriguez-Torres M, Rockstroh J, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351:438-50.
16. Hemingway H, Croft P, Perel P, et al. Prognosis research strategy (PROGRESS) 1: a framework for researching clinical outcomes. BMJ 2013; 346:e5595.
17. Rücker G, Schwarzer G, Carpenter J, Olkin I. Why add anything to nothing? The arcsine difference as a measure of treatment effect in meta-analysis with zero cells. Stat Med 2009; 28:721-38.
18. Nyaga V, Arbyn M, Aerts M. Metaprop: a Stata command to perform meta-analysis of binomial data. Arch Public Health 2014; 72:39.
19. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-87.
20. Howe A, Long J, Nickle D, et al. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antiviral Res 2015; 113:71-8.
21. Koh C, Heller T, Haynes-Williams V, et al. Long-term outcome of chronic hepatitis C after sustained virological response to interferon-based therapy. Aliment Pharmacol Ther 2013; 37:887-94.
22. Hara K, RiveraM, Koh C, et al. Sequence analysis of hepatitis C virus from patients with relapse after a sustained virological response: relapse or reinfection? J Infect Dis 2014; 209:38-45.
23. Manns M, Pockros P, Norkrans G, et al. Long-term clearance of hepatitis C virus following interferon ?-2b or peginterferon ?-2b, alone or in combination with ribavirin. J Viral Hepat 2013; 20:524-9.
24. Giordanino C, Sacco M, Ceretto S, et al. Durability of the response to peginterferon-?2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting. Eur J Gastroenterol Hepatol 2014; 26:52-8.
25. Hotho D, de Bruijne J, Spaan M, et al. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up. J Viral Hepat 2013; 20: e78-81.
26. Ignatova T, Lopatkina T, Chulanov V, et al. Long-term results of antiviral therapy in patients with chronic hepatitis C with sustained virologic response. RJGHC 2013; 23:30-6.
27. Papastergiou V, Stampori M, Lisgos P, Pselas C, Prodromidou K, Karatapanis S. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study. Eur J Gastroenterol Hepatol 2013; 25:798-805.
28. Rahman M, Ahmed D, Masud H, et al. Sustained virological response after treatment in patients with chronic hepatitis C infection-a five year follow up. Bangladesh Med Res Counc Bull 2013; 39:11-3.
29. Rutter k, Hofer H, Beinhardt S, et al. Durability of SVR in chronic hepatitis C patients treated with peginterferon-?2a/ribavirin in combination with a direct-acting anti-viral. Aliment Pharmacol Ther 2013; 38:118-23.
30. Torres Ibarra R, Castelo Lopez D, Alcala Martinez E. Long-term clinical outcome of Mexican patients with chronic hepatitis C infection after sustained virological response to antiviral therapy. Washington, DC: AASLD, 2013. p. Abst#1973.
31. Uyanikoglu A, Kaymakoglu S, Danalioglu A, et al. Durability of sustained virologic response in chronic hepatitis C. Gut Liver 2013; 7:458-61.
32. Li Q, Zhang C, Xiong Y, et al. Long-term assessment of relapse and associated risk factors in chronic hepatitis C patients treated with interferon and ribavirin. Zhonghua Gan Zang Bing Za Zhi 2012; 20:353-6.
33. Maruoka D, Imazeki F, Arai M, Kanda T, Fujiwara K, Yokosuka O. Longitudinal changes of the laboratory data of chronic hepatitis C patients with sustained virological response on long-term follow-up. J Viral Hepat 2012; 19:e97-104.
34. Choi S, Lee Y, Lee J, et al. Durability of a sustained virological response in chronic hepatitis C patients treated with pegylated interferon alfa and ribavirin. Korean J Hepatol 2011; 17:183-8.
35. Morisco F, Stroffolini T, Granata R, Donnarumma L, Guarino M, Caporaso N. Long-term clinical, biochemical and virological outcomes after successful HCVtherapy. J Hepatol 2011; 54(suppl):S61-208.
36. Puig-del-Castillo I, Miguel Planas M, Vergara Gomez M, et al. Five-year follow-up of patients with chronic C hepatitis and sustained virological response. Rev Esp Enferm Dig 2011; 103:56-61.
37. Trapero-Marugán M, Mendoza J, Chaparro M, et al. Long-term outcome of chronic hepatitis C patients with sustained virological response to peginterferon plus ribavirin. World J Gastroenterol 2011; 17:493-8.
38. da Costa Ferreira S, Carneiro Mde V, Souza F, et al. Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon. Braz J Infect Dis 2010; 14:330-4.
39. De Jesús J, Nieves-Santiago P, Rodríguez-Pérez F, Toro D. Sustained virologic response among Latino veterans; does it represent the cure of chronic hepatitis C infection? P R Health Sci J 2010; 29:397-401.
40. Giannini E, Basso M, Savarino V, Picciotto A. Sustained virological response to pegylated interferon and ribavirin is maintained during long-term follow-up of chronic hepatitis C patients. Aliment Pharmacol Ther 2010; 31:502-8.
41. Kim S, Park N, Nam K, et al. Relapse rate after pegylated interferon alpha 2a and ribavirin therapy. Hepatol Int 2010; 4(suppl):94-345.
42. Lee J, Yoon N, Kim J, et al. Durability of sustained virologic response in chronic hepatitis C: analysis of factors related to relapse after sustained virologic response with peginterferon plus ribavirin combination therapy. Korean J Gastroenterol 2011; 57:173-9.
43. Morgan T, Ghany M, Kim H, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010; 52:833-44.
44. Sood A, Midha V, Mehta V, et al. How sustained is sustained viral response in patients with hepatitis C virus infection? Indian J Gastroenterol 2010; 29:112-5.
45. Swain M, Lai M, Shiffman M, et al. A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin. Gasteroenterology 2010; 139:1593-601.
46. George S, Bacon B, Brunt E, Mihindukulasuriya K, Hoffmann J, Di Bisceglie A. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 2009; 49:729-38.
47. Hofer H, Scherzer T, Beinhardt S, et al. Long term follow-up of chronic hepatitis C patients after interferon based anti-viral therapy. Hepatology 2009; 50(4 (suppl)): 680A.
48. Kim C, Park B, Lee J, et al. Durability of a sustained virologic response in combination therapy with interferon/peginterferon and ribavirin for chronic hepatitis C. Korean J Hepatol 2009; 15:70-9.
49. Maylin S, Martinot-Peignoux M, Moucari R, et al. Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C. Gastroenterology 2008; 135:821-9.
50. Adamek A, Adamek J, Juszczyk J, Beresynska I. Long-term viral response to interferon alpha 2b plus ribavirin in chronic hepatitis C patients during standard therapy. Przegl Epidemiol 2007; 61:765-70.
51. Chavalitdhamrong D, Tanwandee T. Long-term outcomes of chronic hepatitis C patients with sustained virological response at 6 months after the end of treatment. World J Gastroenterol 2006; 12:5532-5.
52. Ciancio A, Smedile A, Giordanino C, et al. Long-term follow-up of previous hepatitis C virus positive nonresponders to interferon monotherapy successfully retreated with combination therapy: are they really cured? Am J Gastroenterol 2006; 101:1811-6.
53. Desmond C, Roberts S, Dudley F, et al. Sustained virological response rates and durability of the response to interferon-based therapies in hepatitis C patients treated in the clinical setting. J Viral Hepat 2006; 13:311-5.
54. Moreno M, Pérez-Alvarez R, Rodrigo L, Pérez-López R, Suárez-Leiva P. Long-term evolution of serum and liver viral markers in patients treated for chronic hepatitis C and sustained response. J Viral Hepat 2006; 13:28-33.
55. Yu M, Dai C, Chen S, et al. High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study. BMC Infect Dis 2005; 5:27.
56. Khokhar N. Late relapse in chronic hepatitis C after sustained viral response to interferon and ribavirin. J Gastroenterol Hepatol 2004; 19:471-2.
57. Tsuda N, Yuki N, Mochizuki K, et al. Long-term clinical and virological outcomes of chronic hepatitis C after successful interferon therapy. J Med Virol 2004; 74:406-13.
58. Veldt B, Saracco G, Boyer N, et al. Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy. Gut 2004; 53:1504-8.
59. Ponsoda Arlettaz P, Blanc P, Pageaux G, Ramos J, Ducos J, Larrey D. Absence of long term relapse in patients with a good virological response at 6 months after treatment for chronic hepatitis C. J Hepatol 2002; 36(suppl 1):125.
60. Diago M, Luján M, Valeros D, et al. Long-term response to interferon plus ribavirin in patients with chronic hepatitis C refractory to interferon. Rev Esp Enferm Dig 2001; 93:353-63.